Short Interest in UCB SA (OTCMKTS:UCBJF) Drops By 63.1%

UCB SA (OTCMKTS:UCBJF - Get Free Report) was the recipient of a large decline in short interest in April. As of April 15th, there was short interest totalling 215,500 shares, a decline of 63.1% from the March 31st total of 584,000 shares. Based on an average trading volume of 200 shares, the days-to-cover ratio is currently 1,077.5 days. Approximately 0.1% of the company's stock are short sold.

UCB Price Performance

UCBJF remained flat at $150.70 during trading on Thursday. The stock's fifty day simple moving average is $173.92 and its 200-day simple moving average is $182.40. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.19 and a quick ratio of 0.78. UCB has a 52 week low of $126.05 and a 52 week high of $209.66.

UCB Company Profile

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.